Fluidigm Announces First Quarter 2020 Financial Results
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for Ultrahigh-Throughput COVID-19 Tests on the BioMark platform Maxpar …